{"id":"NCT01614912","sponsor":"Sumitomo Pharma Co., Ltd.","briefTitle":"Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","officialTitle":"Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2012-06-08","resultsPosted":"2018-10-19","lastUpdate":"2022-04-12"},"enrollment":284,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"SM-13496","otherNames":[]}],"arms":[{"label":"SM-13496","type":"EXPERIMENTAL"}],"summary":"The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.","primaryOutcome":{"measure":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint","timeFrame":"DB baseline and up to 32 weeks (LOCF endpoint)","effectByArm":[{"arm":"SM-13496 (Lurasidone HCl) 40-mg or 80-mg Group","deltaMin":-28.4,"sd":22.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":4,"countries":["Japan","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":282},"commonTop":["Insomnia","Akathisia","Nasopharyngitis","Anxiety","Nausea"]}}